Demarest, Phillip
Rustamov, Nabi
Swift, James
Xie, Tao
Adamek, Markus
Cho, Hohyun
Wilson, Elizabeth
Han, Zhuangyu
Belsten, Alexander
Luczak, Nicholas
Brunner, Peter
Haroutounian, Simon
Leuthardt, Eric C.
Article History
Received: 23 May 2023
Accepted: 30 January 2024
First Online: 10 February 2024
Competing interests
: The study was supported, in part, by start-up funding from Washington University Department of Anesthesiology to Simon Haroutounian. This work was also supported by the National Institutes of Health (NIH) grants R01-EB026439, U24-NS109103, P41-EB018783, and Fondazione Neurone. Simon Haroutounian has received in the past 36Â months research grants and contracts from the US National Institutes of Health, US Department of Defense, Patient-Centered Outcomes Research Institute and Eli Lilly, and personal fees from Vertex Pharmaceuticals, Rafa Laboratories and GW Pharma, outside the scope of submitted work. Eric Leuthardt has stock ownership in Neurolutions, Osteovantage, Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev, Inflexion Vascular, Aurenar, and Petal Surgical. He is a consultant for E15, Neurolutions, Inc., and Petal Surgical. Washington University owns equity in Neurolutions. All other authors do not report any conflicts of interest.